Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00368212 · ClinicalTrials.gov registry record · Phase 3
Integrated Treatment Program for Hypochondriasis in Primary Care Settings
A Phase 3 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 91
- Enrollment target
NCT00368212: Completed Phase 3 study, sponsored by Brigham and Women's Hospital.
NCT00368212 is a Phase 3 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 91 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00368212, a Phase 3 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 91 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness of an integrated three-part treatment program in improving the quality of care and treatment outcomes of people with hypochondriasis in primary care settings.
Interventions
- BEHAVIORAL Relaxation response training
- BEHAVIORAL Psychoeducational counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
What the finished NCT00368212 record still lists
NCT00368212 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Relaxation response training is the first listed.
NCT00368212 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00368212 about?
NCT00368212 is a clinical study titled "Integrated Treatment Program for Hypochondriasis in Primary Care Settings". This study will evaluate the effectiveness of an integrated three-part treatment program in improving the quality of care and treatment outcomes of people with hypochondriasis in primary care settings.
What is the current status of trial NCT00368212?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 91 participants. The study started on 2005-05. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00368212?
The interventions under investigation include: Relaxation response training (BEHAVIORAL), Psychoeducational counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT00368212?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00368212's enrollment target sits among peer trials
91 1724th of 2000 higher than 277 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia